Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Tröster AI[au]:

Search results

Items: 1 to 50 of 132

1.

Risk of Parkinson's disease dementia related to level I MDS PD-MCI.

Hoogland J, Boel JA, de Bie RMA, Schmand BA, Geskus RB, Dalrymple-Alford JC, Marras C, Adler CH, Weintraub D, Junque C, Pedersen KF, Mollenhauer B, Goldman JG, Tröster AI, Burn DJ, Litvan I, Geurtsen GJ; MDS Study Group “Validation of Mild Cognitive Impairment in Parkinson Disease”.

Mov Disord. 2019 Mar;34(3):430-435. doi: 10.1002/mds.27617. Epub 2019 Jan 17.

PMID:
30653248
2.

Detecting Mild Cognitive Deficits in Parkinson's Disease: Comparison of Neuropsychological Tests.

Hoogland J, van Wanrooij LL, Boel JA, Goldman JG, Stebbins GT, Dalrymple-Alford JC, Marras C, Adler CH, Junque C, Pedersen KF, Mollenhauer B, Zabetian CP, Eslinger PJ, Lewis SJG, Wu RM, Klein M, Rodriguez-Oroz MC, Cammisuli DM, Barone P, Biundo R, de Bie RMA, Schmand BA, Tröster AI, Burn DJ, Litvan I, Filoteo JV, Geurtsen GJ, Weintraub D; IPMDS Study Group “Validation of Mild Cognitive Impairment in Parkinson Disease”.

Mov Disord. 2018 Nov;33(11):1750-1759. doi: 10.1002/mds.110. Epub 2018 Sep 14. Review.

3.

Reader response: Clinical outcomes of asleep vs awake deep brain stimulation for Parkinson disease.

Tröster AI.

Neurology. 2018 Jul 31;91(5):240-241. doi: 10.1212/WNL.0000000000005899. No abstract available.

PMID:
30061345
4.

Cognitive impairment in Parkinson's disease: a report from a multidisciplinary symposium on unmet needs and future directions to maintain cognitive health.

Goldman JG, Vernaleo BA, Camicioli R, Dahodwala N, Dobkin RD, Ellis T, Galvin JE, Marras C, Edwards J, Fields J, Golden R, Karlawish J, Levin B, Shulman L, Smith G, Tangney C, Thomas CA, Tröster AI, Uc EY, Coyan N, Ellman C, Ellman M, Hoffman C, Hoffman S, Simmonds D.

NPJ Parkinsons Dis. 2018 Jun 26;4:19. doi: 10.1038/s41531-018-0055-3. eCollection 2018. Review.

5.

Strengths and challenges in conducting clinical trials in Parkinson's disease mild cognitive impairment.

Litvan I, Kieburtz K, Tröster AI, Aarsland D.

Mov Disord. 2018 Apr;33(4):520-527. doi: 10.1002/mds.27345. Epub 2018 Mar 24. Review.

PMID:
29573469
6.

Clinical outcomes following awake and asleep deep brain stimulation for Parkinson disease.

Chen T, Mirzadeh Z, Chapple KM, Lambert M, Shill HA, Moguel-Cobos G, Tröster AI, Dhall R, Ponce FA.

J Neurosurg. 2018 Mar 16;130(1):109-120. doi: 10.3171/2017.8.JNS17883.

PMID:
29547091
7.

Initial cognitive changes in Parkinson's disease.

Weintraub D, Tröster AI, Marras C, Stebbins G.

Mov Disord. 2018 Apr;33(4):511-519. doi: 10.1002/mds.27330. Epub 2018 Mar 15. Review.

8.

Successes and optimism in deep brain stimulation for neurological disorders: ripe for a surgical time out?

Tröster AI.

Eur J Neurol. 2018 May;25(5):705-706. doi: 10.1111/ene.13593. Epub 2018 Mar 6. No abstract available.

PMID:
29431884
9.

The Neuropsychology of Movement and Movement Disorders: Neuroanatomical and Cognitive Considerations.

Haaland KY, Dum RP, Mutha PK, Strick PL, Tröster AI.

J Int Neuropsychol Soc. 2017 Oct;23(9-10):768-777. doi: 10.1017/S1355617717000698. Review.

PMID:
29198273
11.

Introduction to the Special Issue on Clinical Neuropsychology of Movement Disorders.

Tröster AI.

Arch Clin Neuropsychol. 2017 Nov 1;32(7):767-768. doi: 10.1093/arclin/acx087.

PMID:
29077801
12.

Mild cognitive impairment as a risk factor for Parkinson's disease dementia.

Hoogland J, Boel JA, de Bie RMA, Geskus RB, Schmand BA, Dalrymple-Alford JC, Marras C, Adler CH, Goldman JG, Tröster AI, Burn DJ, Litvan I, Geurtsen GJ; MDS Study Group “Validation of Mild Cognitive Impairment in Parkinson Disease”.

Mov Disord. 2017 Jul;32(7):1056-1065. doi: 10.1002/mds.27002. Epub 2017 Jun 12.

13.

Memory and mood outcomes after anterior thalamic stimulation for refractory partial epilepsy.

Tröster AI, Meador KJ, Irwin CP, Fisher RS; SANTE Study Group.

Seizure. 2017 Feb;45:133-141. doi: 10.1016/j.seizure.2016.12.014. Epub 2016 Dec 23.

14.

Psychogenic Movement Disorders and Dopamine Transporter Scans: Still a Clinical Diagnosis?

Moguel-Cobos G, Maroney Z, Erickson JM, Tröster AI, Quinn DK.

Psychosomatics. 2017 Jan - Feb;58(1):83-89. doi: 10.1016/j.psym.2016.08.009. Epub 2016 Aug 25. No abstract available.

15.

Neuropsychological outcomes from constant current deep brain stimulation for Parkinson's disease.

Tröster AI, Jankovic J, Tagliati M, Peichel D, Okun MS.

Mov Disord. 2017 Mar;32(3):433-440. doi: 10.1002/mds.26827. Epub 2016 Oct 18.

16.

Cognitive outcome after ventral capsule/ventral striatum stimulation for treatment-resistant major depression.

Kubu CS, Brelje T, Butters MA, Deckersbach T, Malloy P, Moberg P, Tröster AI, Williamson E, Baltuch GH, Bhati MT, Carpenter LL, Dougherty DD, Howland RH, Rezai AR, Malone DA Jr.

J Neurol Neurosurg Psychiatry. 2017 Mar;88(3):262-265. doi: 10.1136/jnnp-2016-313803. Epub 2016 Sep 22.

PMID:
27659923
17.

Proceedings of the Third Annual Deep Brain Stimulation Think Tank: A Review of Emerging Issues and Technologies.

Rossi PJ, Gunduz A, Judy J, Wilson L, Machado A, Giordano JJ, Elias WJ, Rossi MA, Butson CL, Fox MD, McIntyre CC, Pouratian N, Swann NC, de Hemptinne C, Gross RE, Chizeck HJ, Tagliati M, Lozano AM, Goodman W, Langevin JP, Alterman RL, Akbar U, Gerhardt GA, Grill WM, Hallett M, Herrington T, Herron J, van Horne C, Kopell BH, Lang AE, Lungu C, Martinez-Ramirez D, Mogilner AY, Molina R, Opri E, Otto KJ, Oweiss KG, Pathak Y, Shukla A, Shute J, Sheth SA, Shih LC, Steinke GK, Tröster AI, Vanegas N, Zaghloul KA, Cendejas-Zaragoza L, Verhagen L, Foote KD, Okun MS.

Front Neurosci. 2016 Apr 6;10:119. doi: 10.3389/fnins.2016.00119. eCollection 2016. Review.

18.

Accuracy of Patient and Care Partner Identification of Cognitive Impairments in Parkinson's Disease-Mild Cognitive Impairment.

Copeland JN, Lieberman A, Oravivattanakul S, Tröster AI.

Mov Disord. 2016 May;31(5):693-8. doi: 10.1002/mds.26619. Epub 2016 Mar 29.

PMID:
27028432
19.

The pattern of gray matter atrophy in Parkinson's disease differs in cortical and subcortical regions.

Lewis MM, Du G, Lee EY, Nasralah Z, Sterling NW, Zhang L, Wagner D, Kong L, Tröster AI, Styner M, Eslinger PJ, Mailman RB, Huang X.

J Neurol. 2016 Jan;263(1):68-75. doi: 10.1007/s00415-015-7929-7.

20.

Parkinson's disease outcomes after intraoperative CT-guided "asleep" deep brain stimulation in the globus pallidus internus.

Mirzadeh Z, Chapple K, Lambert M, Evidente VG, Mahant P, Ospina MC, Samanta J, Moguel-Cobos G, Salins N, Lieberman A, Tröster AI, Dhall R, Ponce FA.

J Neurosurg. 2016 Apr;124(4):902-7. doi: 10.3171/2015.4.JNS1550. Epub 2015 Oct 9.

PMID:
26452116
21.

Validation of the QUEST for German-speaking countries.

Hopfner F, Nebel A, Lyons KE, Tröster AI, Kuhlenbäumer G, Deuschl G, Martinez-Martin P.

Int J Neurosci. 2016;126(2):127-34. doi: 10.3109/00207454.2015.1077241. Epub 2015 Aug 25.

PMID:
26327253
22.

Potential sex differences in nonmotor symptoms in early drug-naive Parkinson disease.

Liu R, Umbach DM, Peddada SD, Xu Z, Tröster AI, Huang X, Chen H.

Neurology. 2015 May 26;84(21):2107-15. doi: 10.1212/WNL.0000000000001609. Epub 2015 Apr 29.

23.

Changes in cognitive abilities after deep brain stimulation for Parkinson disease.

Tröster AI, Massano J.

Neurology. 2015 Mar 31;84(13):e98-9. doi: 10.1212/WNL.0000000000001456. No abstract available.

PMID:
25825472
24.

About deep brain stimulation.

Massano J, Tröster AI.

Neurology. 2015 Mar 31;84(13):e100-1. doi: 10.1212/01.wnl.0000463858.26584.fd. No abstract available.

PMID:
25825468
25.

Long-term efficacy and safety of thalamic stimulation for drug-resistant partial epilepsy.

Salanova V, Witt T, Worth R, Henry TR, Gross RE, Nazzaro JM, Labar D, Sperling MR, Sharan A, Sandok E, Handforth A, Stern JM, Chung S, Henderson JM, French J, Baltuch G, Rosenfeld WE, Garcia P, Barbaro NM, Fountain NB, Elias WJ, Goodman RR, Pollard JR, Tröster AI, Irwin CP, Lambrecht K, Graves N, Fisher R; SANTE Study Group.

Neurology. 2015 Mar 10;84(10):1017-25. doi: 10.1212/WNL.0000000000001334. Epub 2015 Feb 6.

26.

Proceedings of the Second Annual Deep Brain Stimulation Think Tank: What's in the Pipeline.

Gunduz A, Morita H, Rossi PJ, Allen WL, Alterman RL, Bronte-Stewart H, Butson CR, Charles D, Deckers S, de Hemptinne C, DeLong M, Dougherty D, Ellrich J, Foote KD, Giordano J, Goodman W, Greenberg BD, Greene D, Gross R, Judy JW, Karst E, Kent A, Kopell B, Lang A, Lozano A, Lungu C, Lyons KE, Machado A, Martens H, McIntyre C, Min HK, Neimat J, Ostrem J, Pannu S, Ponce F, Pouratian N, Reymers D, Schrock L, Sheth S, Shih L, Stanslaski S, Steinke GK, Stypulkowski P, Tröster AI, Verhagen L, Walker H, Okun MS.

Int J Neurosci. 2015;125(7):475-85. doi: 10.3109/00207454.2014.999268. Epub 2015 May 25. Review.

27.

The tools of the trade: a state of the art "How to Assess Cognition" in the patient with Parkinson's disease.

Marras C, Tröster AI, Kulisevsky J, Stebbins GT.

Mov Disord. 2014 Apr 15;29(5):584-96. doi: 10.1002/mds.25874. Review.

PMID:
24757108
28.

Parkinson's disease mild cognitive impairment: application and validation of the criteria.

Geurtsen GJ, Hoogland J, Goldman JG, Schmand BA, Tröster AI, Burn DJ, Litvan I; MDS Study Group on the Validation of PD-MCI Criteria.

J Parkinsons Dis. 2014;4(2):131-7. doi: 10.3233/JPD-130304. Review.

29.

Neuropsychological outcomes after psychosocial intervention for depression in Parkinson's disease.

Dobkin RD, Tröster AI, Rubino JT, Allen LA, Gara MA, Mark MH, Menza M.

J Neuropsychiatry Clin Neurosci. 2014 Winter;26(1):57-63. doi: 10.1176/appi.neuropsych.12120381.

30.

Deep brain stimulation may improve quality of life in people with Parkinson's disease without affecting caregiver burden.

Oyama G, Okun MS, Schmidt P, Tröster AI, Nutt J, Go CL, Foote KD, Malaty IA; NPF-QII Investigators.

Neuromodulation. 2014 Feb;17(2):126-32.

PMID:
24024760
31.

Research on the premotor symptoms of Parkinson's disease: clinical and etiological implications.

Chen H, Burton EA, Ross GW, Huang X, Savica R, Abbott RD, Ascherio A, Caviness JN, Gao X, Gray KA, Hong JS, Kamel F, Jennings D, Kirshner A, Lawler C, Liu R, Miller GW, Nussbaum R, Peddada SD, Rick AC, Ritz B, Siderowf AD, Tanner CM, Tröster AI, Zhang J.

Environ Health Perspect. 2013 Nov-Dec;121(11-12):1245-52. doi: 10.1289/ehp.1306967. Epub 2013 Aug 9. Review.

32.

Criteria for the diagnosis of corticobasal degeneration.

Armstrong MJ, Litvan I, Lang AE, Bak TH, Bhatia KP, Borroni B, Boxer AL, Dickson DW, Grossman M, Hallett M, Josephs KA, Kertesz A, Lee SE, Miller BL, Reich SG, Riley DE, Tolosa E, Tröster AI, Vidailhet M, Weiner WJ.

Neurology. 2013 Jan 29;80(5):496-503. doi: 10.1212/WNL.0b013e31827f0fd1.

33.

Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines.

Litvan I, Goldman JG, Tröster AI, Schmand BA, Weintraub D, Petersen RC, Mollenhauer B, Adler CH, Marder K, Williams-Gray CH, Aarsland D, Kulisevsky J, Rodriguez-Oroz MC, Burn DJ, Barker RA, Emre M.

Mov Disord. 2012 Mar;27(3):349-56. doi: 10.1002/mds.24893. Epub 2012 Jan 24. Review.

34.

Subthalamic deep brain stimulation with a constant-current device in Parkinson's disease: an open-label randomised controlled trial.

Okun MS, Gallo BV, Mandybur G, Jagid J, Foote KD, Revilla FJ, Alterman R, Jankovic J, Simpson R, Junn F, Verhagen L, Arle JE, Ford B, Goodman RR, Stewart RM, Horn S, Baltuch GH, Kopell BH, Marshall F, Peichel D, Pahwa R, Lyons KE, Tröster AI, Vitek JL, Tagliati M; SJM DBS Study Group.

Lancet Neurol. 2012 Feb;11(2):140-9. doi: 10.1016/S1474-4422(11)70308-8. Epub 2012 Jan 11. Erratum in: Lancet Neurol. 2012 Mar;11(3):208.

PMID:
22239915
35.

Deep brain stimulation and neuropsychology: a step forward?

Tröster AI.

Nat Rev Neurol. 2011 Aug 9;7(9):480-1. doi: 10.1038/nrneurol.2011.122. No abstract available.

PMID:
21826094
36.

MDS Task Force on mild cognitive impairment in Parkinson's disease: critical review of PD-MCI.

Litvan I, Aarsland D, Adler CH, Goldman JG, Kulisevsky J, Mollenhauer B, Rodriguez-Oroz MC, Tröster AI, Weintraub D.

Mov Disord. 2011 Aug 15;26(10):1814-24. doi: 10.1002/mds.23823. Epub 2011 Jun 9. Review.

37.

A précis of recent advances in the neuropsychology of mild cognitive impairment(s) in Parkinson's disease and a proposal of preliminary research criteria.

Tröster AI.

J Int Neuropsychol Soc. 2011 May;17(3):393-406. doi: 10.1017/S1355617711000257. Review.

PMID:
21473805
38.

Manganese accumulation in the olfactory bulbs and other brain regions of "asymptomatic" welders.

Sen S, Flynn MR, Du G, Tröster AI, An H, Huang X.

Toxicol Sci. 2011 May;121(1):160-7. doi: 10.1093/toxsci/kfr033. Epub 2011 Feb 9.

39.

A differential deficit in time- versus event-based prospective memory in Parkinson's disease.

Raskin SA, Woods SP, Poquette AJ, McTaggart AB, Sethna J, Williams RC, Tröster AI.

Neuropsychology. 2011 Mar;25(2):201-9. doi: 10.1037/a0020999.

40.

A recommended scale for cognitive screening in clinical trials of Parkinson's disease.

Chou KL, Amick MM, Brandt J, Camicioli R, Frei K, Gitelman D, Goldman J, Growdon J, Hurtig HI, Levin B, Litvan I, Marsh L, Simuni T, Tröster AI, Uc EY; Parkinson Study Group Cognitive/Psychiatric Working Group.

Mov Disord. 2010 Nov 15;25(15):2501-7. doi: 10.1002/mds.23362.

41.

Neuropsychology of deep brain stimulation in neurology and psychiatry.

Troster AI.

Front Biosci (Landmark Ed). 2009 Jan 1;14:1857-79. Review.

PMID:
19273169
42.

Neuropsychology of dementia with Lewy bodies.

Kaufer DI, Tröster AI.

Handb Clin Neurol. 2008;88:549-66. doi: 10.1016/S0072-9752(07)88029-8. Review. No abstract available.

PMID:
18631712
43.

A comparison of Parkinson's disease symptoms and self-reported functioning and well being.

Lyons KE, Pahwa R, Troster AI, Koller WC.

Parkinsonism Relat Disord. 1997 Dec;3(4):207-9.

PMID:
18591077
44.

Short-term cognitive and affective outcomes after subthalamic deep brain stimulation for Parkinson's disease.

Tröster AI.

Lancet Neurol. 2008 Jul;7(7):565-7. doi: 10.1016/S1474-4422(08)70115-7. Epub 2008 Jun 4. No abstract available.

PMID:
18538635
45.

Executive dysfunction and neuropsychiatric symptoms predict lower health status in essential tremor.

Woods SP, Scott JC, Fields JA, Poquette A, Tröster AI.

Cogn Behav Neurol. 2008 Mar;21(1):28-33. doi: 10.1097/WNN.0b013e3181684414.

PMID:
18327020
46.
47.

Scales to assess psychosis in Parkinson's disease: Critique and recommendations.

Fernandez HH, Aarsland D, Fénelon G, Friedman JH, Marsh L, Tröster AI, Poewe W, Rascol O, Sampaio C, Stebbins GT, Goetz CG.

Mov Disord. 2008 Mar 15;23(4):484-500. doi: 10.1002/mds.21875.

PMID:
18175343
48.

Assessing cognitive change in Parkinson's disease: development of practice effect-corrected reliable change indices.

Tröster AI, Woods SP, Morgan EE.

Arch Clin Neuropsychol. 2007 Aug;22(6):711-8. Epub 2007 Jul 17.

49.

Asymmetrical ventricular enlargement in Parkinson's disease.

Huang X, Lee YZ, McKeown M, Gerig G, Gu H, Lin W, Lewis MM, Ford S, Tröster AI, Weinberger DR, Styner M.

Mov Disord. 2007 Aug 15;22(11):1657-60.

PMID:
17588238
50.

The use, education, training and supervision of neuropsychological test technicians (psychometrists) in clinical practice. Official statement of the National Academy of Neuropsychology.

Puente AE, Adams R, Barr WB, Bush SS; NAN Policy and Planning Committee, Ruff RM, Barth JT, Broshek D, Koffler SP, Reynolds C, Silver CH, Tröster AI; National Academy of Neuropsychology.

Arch Clin Neuropsychol. 2006 Dec;21(8):837-9. No abstract available.

PMID:
17195315

Supplemental Content

Loading ...
Support Center